Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial

World J Gastroenterol. 2006 Oct 21;12(39):6310-5. doi: 10.3748/wjg.v12.i39.6310.

Abstract

Aim: To evaluate the gastric emptying inhibitory effects of sugar and levodopa on H pylori eradication period.

Methods: A total of 139 consecutive patients were randomized into 6 groups. The participants with peptic ulcer disease or non-ulcer dyspepsia non-responding to other medications who were also H pylori-positive patients either with positive rapid urease test (RUT) or positive histology were included. All groups were pretreated with omeprazole for 2 d and then treated with quadruple therapy regimen (omeprazole, bismuth, tetracycline and metronidazole); all drugs were given twice daily. Groups 1 and 2 were treated for 3 d, groups 3, 4 and 5 for 7 d, and group 6 for 14 d. Groups 1 to 4 received sugar in the form of 10% sucrose syrup. Levodopa was prescribed for groups 1 and 3. Patients in groups 2 and 4 were given placebo for levodopa and groups 5 and 6 received placebos for both sugar and levodopa. Upper endoscopy and biopsies were carried out before treatment and two months after treatment. Eradication of H pylori was assessed by RUT and histology 8 wk later.

Results: Thirty patients were excluded. Per-protocol analysis showed successful eradication in 53% in group 1, 56% in group 2, 58% in group 3, 33.3% in group 4, 28% in group 5, and 53% in group 6. Eradication rate, patient compliance and satisfaction were not significantly different between the groups.

Conclusion: It seems that adding sugar or levodopa or both to anti H pylori eradication regimens may lead to shorter duration of treatment.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antacids / pharmacology
  • Antacids / therapeutic use
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use
  • Anti-Ulcer Agents / pharmacology
  • Anti-Ulcer Agents / therapeutic use
  • Bismuth / pharmacology
  • Bismuth / therapeutic use
  • Dopamine Agents / pharmacology
  • Double-Blind Method
  • Dyspepsia / drug therapy
  • Dyspepsia / etiology
  • Gastric Emptying / drug effects
  • Gastric Emptying / physiology*
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / physiopathology
  • Helicobacter pylori / drug effects*
  • Humans
  • Levodopa / pharmacology*
  • Metronidazole / pharmacology
  • Metronidazole / therapeutic use
  • Omeprazole / pharmacology
  • Omeprazole / therapeutic use
  • Peptic Ulcer / drug therapy
  • Peptic Ulcer / etiology
  • Sucrose / pharmacology*
  • Tetracycline / pharmacology
  • Tetracycline / therapeutic use
  • Treatment Outcome

Substances

  • Antacids
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Anti-Ulcer Agents
  • Dopamine Agents
  • Metronidazole
  • Levodopa
  • Sucrose
  • Tetracycline
  • Omeprazole
  • Bismuth